Ocular Therapeutix OCUL
NASDAQ OCUL
$6.45 -0.20 (-3.01%)
As of: Oct 21, 2026 · 1:53 PM EDT

Ocular Therapeutix (OCUL) EBITDA Margin (2014 - 2026)

Updated

Ocular Therapeutix (OCUL) recorded EBITDA Margin of -595.61% in Q2 2026, down 100.66 percentage points from -494.95% a year earlier but up 257.96 percentage points from the prior quarter.

Analysis

Ocular Therapeutix (OCUL) EBITDA Margin (2014 - 2026) Analysis & Trends

On a TTM basis, Ocular Therapeutix's EBITDA Margin came in at -592.57% as of Jun 30, 2026, down 196.88 percentage points year-over-year; for FY2025, it was -511.43%, down 247.80 percentage points from FY2024.

  • Annual EBITDA Margin has a five-year change of -166.24 percentage points (FY2020 to FY2025).
  • Across earlier years, EBITDA Margin came in at -263.63% in FY2024 (-127.78 pp), -135.86% in FY2023 (+12.79 pp), -148.65% in FY2022 (+25.09 pp) and -173.74% in FY2021 (+171.45 pp).
  • Quarterly EBITDA Margin has ranged from -853.57% in Q1 2026 to -121.50% in Q3 2023 over the past five years.
  • On a year-over-year basis, EBITDA Margin has declined for ten consecutive quarters, with an average year-over-year change of -214.21 percentage points over the last eight quarters.
  • Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 135.70 percentage points in Q1 2022, against a drop of 380.52 percentage points in Q1 2025 at the low end.
  • Per Business Quant, the preceding three quarters came in at -853.57% (Q1 2026), -517.08% (Q4 2025) and -465.00% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,134.24 Bn 1,102.83 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 616.05 Bn 534.58 Bn 17.26 Bn 35.95%
3 AbbVie 500.90 Bn 474.01 Bn 12.70 Bn 49.01%
4 Merck 367.17 Bn 321.54 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn -
6 Astrazeneca 261.35 Bn 235.03 Bn 12.86 Bn 33.11%
7 Amgen 235.77 Bn 191.17 Bn 7.24 Bn 46.01%
8 Gilead Sciences 190.70 Bn 164.90 Bn 6.22 Bn -124.26%
9 Pfizer 169.35 Bn 115.99 Bn 10.94 Bn 39.16%
10 Ocular Therapeutix 1.45 Bn -896.23 Mn 11.46 Mn -590.86%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -590.86%
Mar 31, 2026 -840.76%
Dec 31, 2025 -513.34%
Sep 30, 2025 -459.78%
Jun 30, 2025 -489.69%
Mar 31, 2025 -574.87%
Dec 31, 2024 -287.14%
Sep 30, 2024 -287.96%
Jun 30, 2024 -255.85%
Mar 31, 2024 -194.46%
Dec 31, 2023 -118.50%
Sep 30, 2023 -107.76%
Jun 30, 2023 -122.91%
Mar 31, 2023 -155.81%
Dec 31, 2022 -125.28%
Sep 30, 2022 -165.57%
Jun 30, 2022 -148.04%
Mar 31, 2022 -122.01%
Dec 31, 2021 -132.36%
Sep 30, 2021 -146.28%
API Access

Ocular Therapeutix EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=OCUL&period=max&api_key=YOUR_API_KEY